A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors
Nadine S. Jahchan(AbbVie (United States)), Julien Sage(Stanford University), Joel W. Neal(Stanford Medicine), Margaret Zhou(University of California, Davis), Atul J. Butte(University of California, San Francisco), Joel T. Dudley(Hamilton Thorne (United States)), Alec Palmerton(University of California, Davis), Jonathan W. Riess(University of California Davis Medical Center), Purvesh Khatri(Stanford University), Paweł K. Mazur(The University of Texas MD Anderson Cancer Center), Dedeepya Vaka(University of California, Davis), Kim Q.T. Tran(Stanford University), Dian Yang(Stanford University), Natasha Flores(The University of Texas MD Anderson Cancer Center), Anne‐Flore Zmoos(University of California, Davis), Karolina Krasinska(Stanford University)
Cited by 365
Related Papers
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Systematic pan-cancer analysis of tumour purity
|Nature Communications|2015|1.3k
Gene expression elucidates functional impact of polygenic risk for schizophrenia
|Nature Neuroscience|2016|1.2k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|805